Axa
FOLD

Axa’s Amicus Therapeutics FOLD Stock Holding History

Axa’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-339,638
Closed -$7.84M – 1251
2020
Q4 		$7.84M Sell
339,638
-200,868
-37% -$4.11M 0.02% 581
2020
Q3 		$7.63M Sell
540,506
-42,753
-7% -$623K 0.03% 531
2020
Q2 		$8.8M Sell
583,259
-173,764
-23% -$2.12M 0.03% 465
2020
Q1 		$7M Sell
757,023
-721,087
-49% -$6.85M 0.04% 441
2019
Q4 		$14.4M Buy
1,478,110
+17,398
+1% +$159K 0.06% 361
2019
Q3 		$11.7M Buy
1,460,712
+73,857
+5% +$802K 0.05% 428
2019
Q2 		$17.3M Buy
1,386,855
+8,929
+0.6% +$113K 0.07% 330
2019
Q1 		$18.7M Buy
1,377,926
+159,235
+13% +$1.95M 0.07% 317
2018
Q4 		$11.7M Hold
1,218,691
– – 0.05% 392
2018
Q3 		$14.7M Buy
1,218,691
+646,739
+113% +$9.04M 0.05% 376
2018
Q2 		$8.93M Buy
571,952
+60,453
+12% +$914K 0.03% 483
2018
Q1 		$7.69M Sell
511,499
-6,491
-1% -$98.8K 0.03% 533
2017
Q4 		$7.45M Sell
517,990
-182
-0% -$2.5K 0.03% 558
2017
Q3 		$7.81M Sell
518,172
-809,371
-61% -$10.7M 0.03% 511
2017
Q2 		$13.4M Sell
1,327,543
-840,815
-39% -$6.77M 0.06% 353
2017
Q1 		$15.5M Buy
2,168,358
+36
+0% +$228 0.07% 322
2016
Q4 		$10.8M Buy
+2,168,322
New +$15M 0.05% 391
2015
Q4 		– Sell
-578,343
Closed -$8.09M – 1432
2015
Q3 		$8.09M Buy
+578,343
New +$9.07M 0.03% 435
2014
Q2 		– Sell
-97,740
Closed -$202K – 1398
2014
Q1 		$202K Buy
97,740
+3,319
+4% +$8.3K ﹤0.01% 1221
2013
Q4 		$222K Buy
94,421
+4,767
+5% +$10.5K ﹤0.01% 1209
2013
Q3 		$208K Buy
89,654
+16,822
+23% +$42.2K ﹤0.01% 1137
2013
Q2 		$170K Buy
+72,832
New +$224K ﹤0.01% 1123

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Axa's FOLD Position: Q1 2021 in Review

Axa sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 339,638 shares — an estimated $7.84M sold.

Axa first reported a position in FOLD in Q2 2013 and held it in 22 quarters. The position peaked at $18.7M in Q1 2019. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Axa reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Axa sold 339,638 Amicus Therapeutics shares in Q1 2021, an estimated $7.84M.
  • Axa first reported a position in Amicus Therapeutics in Q2 2013 and held it in 22 quarters.
  • Axa's Amicus Therapeutics position peaked at $18.7M in Q1 2019.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Axa's 13F filing for Q1 2021, filed 14 May 2021.